

Amgen vs Gilead Sciences
Established biotech company selling proven biologic medicines vs Major antiviral and cancer drugmaker. Which is the better buy for your portfolio in November 2026? Plain-English answer below.
Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates HIV and liver disease treatments and has spent years trying to diversify into oncology. Both large-cap biotechs generate prodigious free cash flow and return capital aggressively, yet their pipeline profiles and therapeutic concentrations differ significantly. The Amgen vs Gilead Sciences breakdown shows investors how patent cliff exposure, pipeline depth, and capital allocation choices separate two cash-rich biotech giants navigating the next decade of drug approvals.
Amgen pioneers biologic therapeutics and biosimilars from a massive internal R&D engine and a late-cycle acquisition strategy anchored by the Horizon Therapeutics deal, while Gilead Sciences dominates...
Why It’s Moving

Amgen Faces Legal Settlement and Biosimilar Headwinds Despite Strong Guidance
- A proposed settlement has been announced for the class action securities litigation involving shares purchased between July 2020 and April of this year, introducing legal uncertainty.
- Legacy blockbuster drugs Prolia and XGEVA are experiencing significant erosion due to intense biosimilar competition, forcing reliance on newer pipeline assets to maintain growth.
- Despite these headwinds, Amgen has successfully raised its 2026 financial outlook twice, signaling management confidence that newer drugs are effectively offsetting declines in older portfolios.

Gilead Faces $1.5 Billion Biktarvy Headwind in 2028 Despite Growth Pipeline
- Chief Financial Officer Andy Dickinson disclosed at an investor conference that a negotiated price adjustment for Biktarvy will result in an anticipated $1.5 billion revenue headwind starting in 2028.
- Executives outlined a strategic pivot toward HIV prevention drugs and a potential new cell therapy for multiple myeloma to drive growth beyond the current Biktarvy dependency.
- The company recently completed a new Research Center in Foster City, California, designed to accommodate evolving scientific needs and support the development of inflammation and oncology pipelines.

Amgen Faces Legal Settlement and Biosimilar Headwinds Despite Strong Guidance
- A proposed settlement has been announced for the class action securities litigation involving shares purchased between July 2020 and April of this year, introducing legal uncertainty.
- Legacy blockbuster drugs Prolia and XGEVA are experiencing significant erosion due to intense biosimilar competition, forcing reliance on newer pipeline assets to maintain growth.
- Despite these headwinds, Amgen has successfully raised its 2026 financial outlook twice, signaling management confidence that newer drugs are effectively offsetting declines in older portfolios.

Gilead Faces $1.5 Billion Biktarvy Headwind in 2028 Despite Growth Pipeline
- Chief Financial Officer Andy Dickinson disclosed at an investor conference that a negotiated price adjustment for Biktarvy will result in an anticipated $1.5 billion revenue headwind starting in 2028.
- Executives outlined a strategic pivot toward HIV prevention drugs and a potential new cell therapy for multiple myeloma to drive growth beyond the current Biktarvy dependency.
- The company recently completed a new Research Center in Foster City, California, designed to accommodate evolving scientific needs and support the development of inflammation and oncology pipelines.
Investment Analysis

Amgen
AMGN
Pros
- Amgen maintains a robust oncology portfolio with blockbuster drugs like Lumakras driving consistent revenue growth.
- Rare disease franchise, including Tepezza, provides high-margin recurring revenues and shields against generic erosion.
- Strong balance sheet supports dividend growth and strategic acquisitions amid pipeline advancements.
Considerations
- Biosimilar competition erodes sales of key blockbusters such as Enbrel and Prolia.
- High R&D expenses pressure margins despite obesity drug progress in early stages.
- Regulatory delays in novel assets like MariTide expose pipeline execution risks.

Gilead Sciences
GILD
Pros
- Dominant HIV franchise with Yeztugo launch momentum bolsters market share alongside Descovy's 45% penetration.
- Attractive valuation at forward P/E of 14.19 trades at discount to industry peers.
- Expanding oncology pipeline nears key regulatory milestones for sustained growth.
Considerations
- Upcoming quarterly EPS projected to decline 1.58% year-over-year amid flat revenue.
- Recent insider sales signal potential short-term concerns over performance.
- Modest consensus price target implies limited near-term upside from current levels.
Amgen (AMGN) Next Earnings Date
Amgen has not yet confirmed a date for its next earnings report. Based on the company's historical pattern of reporting approximately three months after the previous quarter, the next release is expected around February 2027. This upcoming report will cover results for the fourth quarter of fiscal year 2026.
Gilead Sciences (GILD) Next Earnings Date
Gilead Sciences has not yet announced a confirmed date for its next earnings report. Based on the historical reporting pattern, which typically occurs approximately three months after the previous release, the upcoming announcement is expected in early February 2027. This report will cover the company's fourth quarter and full-year fiscal results for 2026. Investors should monitor official channels for the precise scheduling of this anticipated disclosure.
Amgen (AMGN) Next Earnings Date
Amgen has not yet confirmed a date for its next earnings report. Based on the company's historical pattern of reporting approximately three months after the previous quarter, the next release is expected around February 2027. This upcoming report will cover results for the fourth quarter of fiscal year 2026.
Gilead Sciences (GILD) Next Earnings Date
Gilead Sciences has not yet announced a confirmed date for its next earnings report. Based on the historical reporting pattern, which typically occurs approximately three months after the previous release, the upcoming announcement is expected in early February 2027. This report will cover the company's fourth quarter and full-year fiscal results for 2026. Investors should monitor official channels for the precise scheduling of this anticipated disclosure.
Buy AMGN or GILD in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.